Tecon Biology's subsidiary completes Beijing Stock Exchange listing guidance

Tecon Biology (SZSE:002100) announced that its subsidiary, Tiankang Pharmaceutical, a company listed on the National Equities Exchange and Quotations (NEEQ: 874339), has completed the guidance and acceptance process for its planned public offering of shares and listing on the Beijing Stock Exchange. On June 18, 2025, Tiankang Pharmaceutical received a letter from the Jiangsu Securities Regulatory Bureau confirming the completion of the guidance work by China Securities. The company's board approved the proposed listing in December 2024. However, Tecon Biology cautions investors that the public offering is subject to regulatory approval and carries the risk of failure.